Norgen’s 2019-nCoV TaqMan RT-PCR Kit Dx provides SARS-CoV-2 detection based on the assays and protocols developed by the CDC.  The kit utilizes RT-PCR for the amplification of specific target sequences and target specific probes for the detection of the amplified cDNA. The Primer & Probe Mixes contain all 3 CDC developed assays in individual tubes where probes are labelled with the fluorophore FAM. All assays are premixed to the working concentrations recommended by the CDC.  The Positive Control contains two nCoV nucleocapsid target gene RNA (N1 and N2) and RNase P (internal control). The kit contains a positive control to monitor for PCR inhibition, and to validate the quality of the sample and the detection result. The 2019-nCoV TaqMan RT-PCR Kit Dx comprises Master Mix for the target and PCR control detection, 3 target Primer & Probe Mixes, as well as a positive control and a negative control (nuclease-free water) to confirm the integrity of the kit reagents.  

Positive results are indicative of SARS-CoV-2 RNA detection, however clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out co-infection with other viruses and therefore the agent detected may not be the definite cause of disease.  Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Any negative results must be combined with clinical observations, patient history, and epidemiological information.

Norgen’s 2019-nCoV TaqMan RT-PCR Kit Dx is intended for use by professional users including clinical laboratory personnel experienced and trained in molecular biology techniques including real-time PCR and in vitro diagnostic procedures.
Norgen’s 2019-nCoV TaqMan RT-PCR Kit Dx was developed and validated to be used with the BioRad CFX96 Touch™ Real-Time PCR Detection System.

Background information

In December 2019, an outbreak of respiratory illness started in Wuhan City, Hubei Province, China and has now spread throughout the world to many different countries.  This respiratory disease was caused by a novel coronavirus and was initially termed “2019 novel coronavirus” or “2019-nCoV”, however in February of 2020 the World Health Organization (WHO) announced that the official name of the disease is COVID-19. The official name of the coronavirus causing COVID-19 is SARS-CoV-2. 

SARS-CoV-2 is a new strain of coronavirus infecting humans that had not been previously detected before the outbreak in China in December 2019. While SARS-CoV-2 is new, many coronaviruses have been known to infect animals and humans for some time. Coronaviruses are known to commonly infect camels, cattle, cats, and bats. In humans, Coronavirus infections can cause various illnesses from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).

Human infection is more severe when the coronavirus has originated in animals and spread to humans, as is the case with MERS and SARS. SARS-CoV-2 is a betacoronavirus, similar to MERS and SARS, both of which have their origins in bats. The animal source of SARS-CoV-2 has not yet been identified, however Chinese officials have linked many of the early cases to a large seafood and live animal market, suggesting that the initial transmission was the result of animal-to-person spread. However, many of the later detected cases did not report any exposure to animal markets, indicating that the virus is now spreading via human-to-human contact.

Symptoms of infection with SARS-CoV-2 can range from milder symptoms such as a runny nose, sore throat, cough, and fever to more severe symptoms including pneumonia or breathing difficulties. In some cases infection with SARS-CoV-2 has resulted in death. As with other respiratory illnesses, older people and individuals with pre-existing medical conditions (such as diabetes or heart disease) are more vulnerable to becoming severely ill with the virus.